"With A Molecule That Is A Million Times Larger Than A Small Molecule, So Many Things Can Go Wrong," Says Biogen Idec Asia Operations Head Gunther Winkler
This article was originally published in PharmAsia News
Executive Summary
Gunther Winkler, Biogen Idec's Senior Vice President, International Business, is responsible for expanding the company's Asia operations. Winkler, a close watcher of biosimilars regulations being adapted by various countries, is skeptical about the safety of copied biotech drugs and therefore calls for sufficient caution on the approval mechanism for such drugs. In an interview with PharmAsia News' India bureau, Gunther Winkler spells out the company's ambitions in Asia, which includes research on products that could be relevant to local populations.
You may also be interested in...
Biogen's MS Drugs Ride High In India, Backed By Special Pricing, Awareness Building And Pharmacovigilance
In the run up to the annual U.S.-India BioPharma & Healthcare Summit, June 23 in Boston, PharmAsia News sat down with key industry players to discuss the state of the pharma industry in India. In the first part of this series, Boston Consulting Group provided a sneak preview of a report commissioned by the USA-India Chamber of Commerce that will be released at the summit ('Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For "Niche Busters" And Stem Cells,' PharmAsia News, May 23, 2011). In this installment, we talk with Biogen Idec SVP Gunther Winkler, who discusses the big biotech's strategy in India and important policy decisions facing the Indian government.
Biogen's MS Drugs Ride High In India, Backed By Special Pricing, Awareness Building And Pharmacovigilance
In the run up to the annual U.S.-India BioPharma & Healthcare Summit, June 23 in Boston, PharmAsia News sat down with key industry players to discuss the state of the pharma industry in India. In the first part of this series, Boston Consulting Group provided a sneak preview of a report commissioned by the USA-India Chamber of Commerce that will be released at the summit ('Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For "Niche Busters" And Stem Cells,' PharmAsia News, May 23, 2011). In this installment, we talk with Biogen Idec SVP Gunther Winkler, who discusses the big biotech's strategy in India and important policy decisions facing the Indian government.
Biogen Idec Senior VP International Business on Expanding Opportunities And Lessons Learned In Asia
Biogen Idec's strategy in emerging markets is not likely to change under the company's new CEO George Scangos, according to Senior VP International Business Gunther Winkler